Research - Conatus Pharmaceuticals (CNAT) will release the combined results from 3 phase 1 and 2 studies on Thursday after the bell. CNAT is up 60% from our suggestion to get long the stock this Fall at $6.00.
PremiumInsights - Arena Pharmaceuticals (ARNA) was up as much as 40% on Wednesday with the release of phase I data for APD334.
Read nowResearch - Solithromycin proves non-inferior to moxifloxacin in phase 3 SOLITAIRE-ORAL trial, meets endpoints endorsed by both U.S. and E.U. regulators. Enrollment update for SOLITAIRE-IV is expected in … Continue Reading
PremiumResearch - Our goal was to roll profit from this short-term trade into a small, longer-term position in SRNE, which we plan to let ride through TRIBECA.
PremiumInsights - Investor/entrepreneur Dr. Patrick Soon-Shiong is making a sizable investment in Sorrento Therapeutics (SRNE), in addition to forming a joint venture with the small company to develop … Continue Reading
Read nowResearch - With data for ONT-380 to be presented at SABCS, Oncothyreon (ONTY) announced it has licensed ONT-380 from partner Array Biopharma (ARRY) for $20 million.
PremiumResearch - Bluebird Bio (BLUE) surprised everyone on Monday evening, exceeding expectations for early data from the LentiGlobin drug candidate.
Read now
